Invega

Paliperidone

Treatment of schizophrenia. Treatment of schizoaffective disorder as monotherapy or adjunct to mood stabilizers &/or antidepressants.

Schizophrenia Adult 6 mg once daily. Dose increases >6 mg/day only after clinical reassessment w/ increments of 3 mg/day at >5 days interval. Recommended range: 3-12 mg once daily. Max: 12 mg/day. Adolescent 12-17 yr 3 mg once daily. Dose increases only after clinical reassessment w/ increments of 3 mg/day at >5 days interval. Schizoaffective disorder Adult 6 mg once daily. Dose increases only after clinical reassessment w/ increments of 3 mg/day at >4 days interval. Recommended range: 3-12 mg once daily. Max: 12 mg/day. Mild renal impairment (CrCl ≥50 to <80 mL/min) 3 mg once daily. Max: 6 mg once daily. Moderate to severe renal impairment (CrCl ≥10 to <50 mL/min) 1.5 mg once daily. Max: 3 mg once daily after clinical reassessment.

May be taken with or without food: Take consistently either always w/ or always w/o food. Swallow whole, do not divide/chew/crush.

Hypersensitivity to paliperidone & risperidone.

Increased mortality w/ dementia-related psychosis. Cerebrovascular adverse events, including stroke, in elderly patients w/ dementia-related psychosis. Discontinue if neuroleptic malignant syndrome or tardive dyskinesia occurs. QTc prolongation, patients w/ congenital QT syndrome & history of cardiac arrhythmias. Monitor for symptoms of hyperglycemia, DM & wt gain. Hyperprolactinemia. Potential for GI obstruction, cognitive & motor impairment. Monitor orthostatic vital signs in patients vulnerable to hypotension. Leukopenia, neutropenia & agranulocytosis. History of seizures, risk for venous thromboembolism, at risk of aspiration pneumonia & Parkinson's disease or dementia w/ Lewy bodies. Close supervision of patients w/ high risk of suicide. Priapism. Thrombotic thrombocytopenic purpura (TTP). Intraoperative floppy iris syndrome. Conditions that contribute to core body temp elevation or dehydration. May impair ability to drive or operate machinery. Pregnancy & lactation. Elderly & childn.

Cerebrovascular adverse events including stroke. Neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, hyperglycemia & DM. Hyperprolactinemia, orthostatic hypotension & syncope. Leukopenia, neutropenia & agranulocytosis. Seizures, dysphagia, suicide attempt, priapism, TTP. Disruption of body temp regulation. Antiemetic effect. Adult EPS, tachycardia, akathisia, somnolence, dyspepsia, constipation, increased wt & nasopharyngitis. Adolescents EPS, somnolence, akathisia, headache, increased wt & tachycardia.

Centrally-acting drugs & alcohol. May antagonize effect of levodopa & other dopamine agonists. Additive effect w/ drugs w/ hypotensive effects. Decreased C_max & AUC w/ carbamazepine. Increased exposure to metabolizers w/ paroxetine. Increased C_max & AUC w/ divalproex.

Antipsychotics

N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.

P₁S₁S₃